findmyKOL
Clinical trialNCT05779930Not, yet, recruitingEarly phase 1Interventional

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

SponsorNationwide Children's HospitalEnrollment12Acute Lymphoblastic Leukemia With Failed RemissionAcute Lymphoblastic Leukemia, in RelapseB Cell LeukemiaB-cell Non Hodgkin LymphomaNon-Hodgkin's Lymphoma RefractoryNon-Hodgkin's Lymphoma, Relapsed
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Nationwide Children'S Hospital

    Columbus, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Oct 2025
Primary completion
31 Dec 2030
Completion
31 Dec 2035
Last update posted
15 Aug 2025
Registered enrollment
12
Registry id
NCT05779930
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.